Asia FX cautious amid US govt shutdown; yen tumbles after Takaichi’s LDP win
VANCOUVER - AbCellera Biologics Inc. (NASDAQ:ABCL), whose stock has surged over 67% in the past year according to InvestingPro data, has dosed the first participants in a Phase 1 clinical trial of ABCL575, an investigational antibody therapy being developed for moderate-to-severe atopic dermatitis, the company announced Wednesday.
ABCL575 targets OX40 ligand and has been engineered with Fc-silencing and half-life extension features that could potentially support dosing once every six months, which would be less frequent than other therapies currently in clinical development.
The randomized, placebo-controlled, double-blind study will assess the safety and tolerability of ABCL575 following subcutaneous administration in healthy participants. Results from this initial clinical trial are expected in mid-2026.
In preclinical studies, the company reported that ABCL575 demonstrated potent inhibition of T cell-mediated inflammatory pathways and a favorable safety profile. The antibody works by disrupting OX40/OX40L signaling, which regulates inflammatory pathways involved in atopic dermatitis.
Beyond atopic dermatitis, AbCellera indicated the therapy might have potential applications for other inflammatory and autoimmune conditions, though specific indications were not detailed.
The clinical-stage biotechnology company, which focuses on discovering and developing antibody-based medicines in endocrinology, women’s health, immunology, and oncology, made the announcement in a press release statement. While analysts don’t expect profitability this year, InvestingPro analysis reveals 8 additional key insights about AbCellera’s financial health and market position in their comprehensive Pro Research Report, available to subscribers.
In other recent news, AbCellera Biologics reported second-quarter 2025 revenue of $17.1 million, marking a substantial 134% increase from the $7.3 million recorded in the same period last year. This revenue figure significantly exceeded analyst expectations, which had projected $7.45 million. The increase was primarily attributed to a milestone payment related to a Trianni license. Additionally, the company reported a quarterly loss of -$0.12 per share, which was better than the anticipated loss of -$0.14 per share and an improvement from the previous year’s -$0.13 per share loss. AbCellera has also announced its transition to a clinical-stage biotechnology firm. In terms of stock ratings, Benchmark has maintained its Hold rating on AbCellera Biologics. These developments highlight the company’s recent progress and financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.